Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we’ve Learned and What Comes Next

• Innes, Rachael ^[1] ; Petrie, John R ^[2] ; Fremming Dejgaard, Thomas ^[3]
  1. [1] School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
  2. [2] School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, Robertson Centre for Biostatistics/ Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, UK
  3. [3] Department of Endocrinology and Nephrology, Nordsjællands Hospital – Hillerød, Hillerød, Denmark

  Mostrar afiliaciones +
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 55, Nº. 3, 2026, págs. 421-435
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Use of daily GLP-1 RAs in T1D is associated with promising reductions in weight and daily insulin dose as well as modest dose-dependent improvements in glycemic control. Blood pressure reductions were noted in some studies. However, their use is not without challenges. Gastrointestinal adverse effects were prominent, leading to treatment discontinuation in some cases. Hypoglycemia and hyperglycemia with ketosis were notable side effects in clinical trials to date but may be mitigated in future,